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Abstract 
Health economic evaluations are relevant to 
those making healthcare resource allocation 
decisions, such as listing a new drug on the 
national formulary or launching a new 
vaccination programme. Compared with 
clinical studies that report only the health 
consequences of an intervention, economic 
evaluations require more space to report 
additional items such as resource use, costs, 
preference-related information, and cost-
effectiveness results. This creates challenges 
for editors, peer reviewers, and those who wish 
to scrutinise a study’s findings. The Con -
solidated Health Economic Evaluation Report -
ing Standards (CHEERS) updated previous 
efforts to produce a single useful reporting 
standard. It received endorsement from, and 
was co-published in, 10 journals that 
frequently publish health economic evalu -
ations. CHEERS provides a sound basis for 
improving the reporting of economic 
evaluations. 
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Introduction 
n
ealth economic evaluation is defined as ‘the 
comparative analysis of alternative courses 
of action in terms of both their costs and their 
consequences’.1  These evaluations are increas -
ingly used for decision-making and are an 
important compo nent of health technology 
assessment (HTA) programmes internationally.2 
The need for economic evaluations to report 
both health consequences of an intervention and 
additional items on resource use, costs, 
preference-related information, and cost-eff ec -
tive ness results creates a challenge for editors, 
peer reviewers, and those who 
wish to scrutinise a study’s 
findings.3 
There is evidence that the 
quality of reporting of 
economic evaluations varies 
widely and could benefit from 
improved quality assurance 
mechanisms.4,5 Transparency 
and structure in reporting is 
especially relevant for health 
economic evaluations because: 
1. the number of published 
studies continues to grow;6  
2. there are potentially major 
consequences from resource 
allocation decisions based on 
mis leading study findings; and 
3. unlike clinical trials, there 
are no widely-implemented 
mechanisms for registering 
studies or making data availa -
ble for independent interrogation or analysis.  
Endorsement of reporting guidelines by 
journals has been shown to improve reporting of 
clinical research.7 The risk of making costly 
decisions due to poor reporting combined with 
the lack of mechanisms that promote accounta -
bility, makes transparency in reporting economic 
evaluations especially important and a primary 
concern among journal editors and decision-
makers.3,8 
 
Development of the Consolidated 
Health Economic Evaluation 
Reporting Standards (CHEERS) 
Following the recommendations of a previous  
task force,9 the International Society for Pharma -
coeconomics and Outcomes 
Research (ISPOR) established 
the CHEERS Task Force to 
improve the reporting of health 
econ omic evaluations. Task 
Force membership consisted of 
health economic journal editors 
and content experts from 
around the world. The Task 
Force used a process consistent 
with that used in the develop -
ment of the EQUATOR suite of 
guidelines, such as CONSORT 
(for the reporting of clinical 
trials) and PRISMA (for the 
reporting of systematic reviews). 
This invol ved consulting a 
Delphi group consisting of 
inter national experts repre -
senting academia, biomedical 
journal editors, the pharma -
ceutical industry, gov ernment 
decision makers, and those in clinical practice. 
CHEERS aimed to consoli date and update 
previous efforts10-21 into a single useful reporting 
standard. It received endorsement from, and was 
co-published in, 10 journals that frequently 
publish economic evaluations. The CHEERS 
reporting standard is not intended to prescribe 
how economic evaluations should be conducted; 
rather, analysts should have the freedom to 
innovate or make their own methodological 
choices.  Its objective is to ensure these choices 
are clearly reported to reviewers and readers. 
Therefore, the CHEERS statement could be used 
to examine the quality of reporting, but it is not 
intended to assess the quality of study methods 
(other checklists have been developed for this 
purpose).22 The primary audience for the 
CHEERS reporting standard are researchers 
reporting economic evaluations, journal editors, 
and peer reviewers of the intended journals. 
CHEERS consists of a 24-item checklist 
accompanied by recommendations on the 
minimum amount of information to be included 
when reporting economic evaluations. It has 
been adopted as an EQUATOR guideline. 
 
The CHEERS checklist 
The CHEERS checklist was published in 2013 
and is shown in Table 1. In the full explanation 
and elaboration document,23  which can be 




tion-and-elaboration), the rationale for each of 
the 24 items is explained and examples given. 
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important and a 
primary concern 
among journal 
editors and  
decision-makers.
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Table 1. CHEERS checklist: Items to include when reporting economic evaluations of health interventions 
 
Section/Item                        Item  No.        Recommendation                                                                                                                                                                     Reported on  
                                                                                                                                                                                                                                                                                            Page no. / Line No. 
Title and abstract 
 
Title                                          1                   Identify the study as an economic evaluation or use more specific terms such as  
“cost-effectiveness analysis”, and describe the interventions compared. 
                                                      
Abstract                                    2                   Provide a structured summary of objectives, perspective, setting, methods (including study  




Background                            3                   Provide an explicit statement of the broader context for the study.                                                                




Target population                4                   Describe characteristics of the base case population and subgroups analysed including  
and subgroups                                             why they were chosen.                                                                                                                                                    
                                                                                                                                                                                                                                                                         
Setting and location             5                   State relevant aspects of the system(s) in which the decision(s) need(s) to be made.                             
                                                                                                                                                                                                                                                                         
Study perspective                 6                   Describe the perspective of the study and relate this to the costs being evaluated.                                   
                                                                                                                                                                                                                                                                         
Comparators                          7                   Describe the interventions or strategies being compared and state why they were chosen.                   
                                                                                                                                                                                                                                                                         
Time horizon                         8                   State the time horizon(s) over which costs and consequences are being evaluated and  
                                                                         say why appropriate.                                                                                                                                                        
                                                                                                                                                                                                                                                                         
Discount rate                          9                   Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.             
                                                                                                                                                                                                                                                                         
Choice of health                   10                 Describe what outcomes were used as the measure(s) of benefit in the evaluation and  
outcomes                                                       their relevance for the type of analysis performed.                                                                                              
                                                                                                                                                                                                                                                                      
Measurement of                    11a               Single study-based estimates: Describe fully the design features of the single effectiveness study  
effectiveness                                                 and why the single study was a sufficient source of clinical effectiveness data.  
                                                     
                                                     11b             Synthesis-based estimates: Describe fully the methods used for identification of included  
                                                                         studies and synthesis of clinical effectiveness data.                                                                                              
                                                                                                                                                                                                                                                                         
Measurement and                12                 If applicable, describe the population and methods used to elicit preferences for outcomes.              
valuation of preference- 
based outcomes                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                         
Estimating resources           13a               Single study-based economic evaluation: Describe approaches used to estimate resource use  
and costs                                                        associated with the alternative interventions. Describe primary or secondary research  
                                                                         methods for valuing each resource item in terms of its unit cost.  
                                                                         Describe any adjustments made to approximate to opportunity costs.                                                         
                                                                                                                                                                                                                                                                        
                                                     13b              Model-base economic evaluation: Describe approaches and data sources used to estimate  
resource use associated with model health states. Describe primary or secondary research  
methods for valuing each resource item in terms of its unit cost. Describe any adjustments  
made to  approximate to opportunity costs. 
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Section/Item                        Item |No.        Recommendation                                                                                                                                                                     Reported on 
                                                                                                                                                                                                                                                                                            Page No. / Line No. 
                                                                                                                                                                                                                                                                        
Currency, price date            14                 Report the dates of the estimated resource quantities and unit costs.  
and conversion                                            Describe methods for adjusting estimated unit costs to the year of reported costs if necessary.  
                                                                         Describe methods for converting costs into a common currency base and the exchange rate. 
                                                     
Choice of model                   15                 Describe and give reasons for the specific type of decision-analytic model used.  
Providing a figure to show model structure is strongly recommended.                                                        
                                                                                                                                                                                                                                                                         
Assumptions                          16                 Describe all structural or other assumptions underpinning the decision-analytic model.                     
                                                                                                                                                                                                                                                                         
Analytic methods                 17                 Describe all analytic methods supporting the evaluation. This could include methods for  
dealing with skewed, missing, or censored data, extrapolation methods, methods for pooling  
data, approaches to validate or make adjustments (e.g., half-cycle corrections) to a model,  




Study parameters                  18                 Report the values, ranges, references, and if used, probability distributions for all parameters.  
Report reasons or sources for distributions used to represent uncertainty where appropriate.  
Providing a table to show the input values is strongly recommended.                                                          
                                                                                                                                                                                                                                                                            
Incremental costs                 19                 For each intervention, report mean values for the main categories of estimated costs and  
and outcomes                                              outcomes of interest, as well as mean differences between the comparator groups.  
                                                                         If applicable, report incremental cost-effectiveness ratios. 
                                                     
Characterising                       20a               Single study-based economic evaluation: Describe the effects of sampling uncertainty for  
uncertainty                                                   estimated  incremental cost, incremental effectiveness and incremental cost-effectiveness,  
                                                                             together with the impact of methodological assumptions (e.g. discount rate, study perspective).           
                                                                                                                                                                                                                                                                      
                                                    20b              Model-based economic evaluation: Describe the effects on the results of uncertainty for all  
input parameters, and uncertainty related to the structure of the model and assumptions. 
                                                     
Characterising                       21                 If applicable, report differences in costs, outcomes or cost-effectiveness that can be explained   
heterogeneity                                               by variations between subgroups of patients with different baseline characteristics or other  
                                                                         observed variability in effects that are not reducible by more information.  
                                                      
Discussion                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                              
Study findings,                      22                 Summarise key study findings and describe how they support the conclusions reached.  
limitations,                                                   Discuss limitations and the generalisability of the findings and how the findings fit with 
generalisability, and                                   current knowledge. 
current knowledge                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                              
Other                                                                                                                                                                                                                                                                  
                                                      
Source of funding                 23                 Describe how the study was funded and the role of the funder in the identification, design,  
conduct and reporting of the analysis. Describe other non-monetary sources of support.                    
                                                                                                                                                                                                                                                                         
Conflicts of Interest             24                 Describe any potential for conflict of interest among study contributors in accordance with  
journal policy. In the absence of a journal policy, we recommend authors comply with  
International Committee of Medical Journal Editors’ recommendations. 
                                                  
Source: Husereau et al.23
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Updating CHEERS 
Study methods and reporting standards may 
change over time, and many of the established 
reporting guidelines, such as CONSORT and 
PRISMA, have been updated periodically. In 
2020, ISPOR decided to update CHEERS, and 
the Task Force was reconvened. 
A number of factors led to the 
update. First, feedback on the 
CHEERS checklist suggested 
that it was in adequate for 
reporting stud ies such as cost-
benefit analyses, which 
measure and value benefits in 
monetary terms.27  In addition, 
a study of the use of the 
CHEERS checklist sugg ested 
that it was often used 
inappropriately. Specifically, it 
was often used to assess the methodological 
quality of published studies, rather than the 
quality of reporting.28 
Second, there have been several important 
develop ments in the methodology of economic 
evaluation that neces sitated modification of the 
current checklist. These include developments in 
the methods for assessing individuals’ prefer -
ences for health and healthcare, more complex 
approaches to mod elling and the characterisation 
of uncertainty, and a growing interest in the 
distributive effects (i.e. impacts 
on equity) within economic 
evaluations. 
Third, there has been a 
growing interest in the 
contribution of patients and 
the general public in designing 
and conducting health services 
research studies, including 
econ omic evalu ations. Patients 
and the general public are also 
increas ingly imp ortant audi -
ences for the results of econ -
omic evalua tions, given their participation as 
stake holders in health tech nology assessment 
(HTA) pro cesses in many jurisdictions. There -
fore, they are interested in knowing which groups 
of patients the study results apply to, whether 
outcomes relevant to patients have been assessed, 
and whether patients have been consulted on the 
design of the study. 
The revision of CHEERS, which is ongoing, 
will respond to these developments. The Task 
Force includes new mem bers with the relevant 
expertise in the main methodological develop -
ments and is being advised by a Patient and 
Public Involvement and Engagement Group with 
plans to report these efforts using the GRIPP2 
guidelines for patient engagement.29 The revised 
CHEERS checklist will be published in 2022 and 
will be endorsed by a number of journals, 




Adequate reporting of research is crucial, 
especially in applied areas of research. Excellent 
research that is poorly reported helps no one. 
This has been recognised by researchers in health 
economic evaluation, and the CHEERS guide -
Continued from page 61
Item 3: Introduction 
 
Recommendation: Provide an explicit 
statement of the broader context for the study. 
Present the study question and its relevance for 
health policy or practice decisions. 
 
Example:  
Many nonsurgical treatments, such as decon -
gestants, antihistamines, antibiotics, mucolytics, 
steroids, and autoinflation, are currently used in 
the UK National Health Service (NHS) as short-
term treatments for otitis media (OME) in an 
attempt to avoid unnecessary secondary referral 
and costly surgery.  However, there is little evidence 
that these nonsurgical options are beneficial.’ 
‘further evaluation should aim to estimate the cost-
effectiveness of topical intranasal corticosteroids in 
order to provide decision-makers with evidence on 
whether the considerable resources currently being 
invested in this area represent an efficient use of 
scarce public resources`….’This paper summarises 
the methods and results of an economic evaluation 
that was based on evidence from the GNOME 
trial (p543) 24 
 
 
Explanation: Economic evaluations may 
examine whether a new intervention should be 
reimbursed or may assess existing health 
interventions. Sometimes, a resource allocation 
question will be researcher- or consumer-driven. 
Increasingly, however, economic evaluations are 
being conducted to meet the needs of decision-
makers who need to understand the con -
sequences of re-allocating healthcare resources. 
If the study was conducted for a decision maker, 
this should be stated. Otherwise, a description of 
the importance of the question should be given. 
It is not enough to state that “The purpose of the 
study was to assess the cost-effectiveness of 
treatment X”.  Correct specification of the study 
question requires details of the study (patient) 
population, the intervention of interest, the 
relevant comparator(s), and the healthcare 
setting. Therefore, reporting on this item needs 
to be considered in conjunction with that for 
CHEERS checklist items 4–7 (i.e. target 
population and subgroups; setting and loca -
tion; study perspective; and comparators) 
described below. A good example of a study 
question would be “We assessed the cost-
effectiveness of etanercept, as compared with 
infliximab, in patients whose rheumatoid 
arthritis was inadequately controlled by 
methotrexate, within the context of the UK 
National Health Service”.  
There have been 
several important 




modification of the 
current checklist.
Examples of CHEERS items #3 and #6. 
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lines have been developed to provide an inter -
national standard for study sponsors, medical 
writers, authors and journals consistent with the 
accepted methodology for EQUATOR guide -
lines. The CHEERS Task Force recognises that 
publishing economic evaluations with sufficient 
information to allow inter pretation and 
replication is quite challenging, as it requires a 
significant amount of text. However, the Task 
Force also assumes these demands are becoming 
easier to meet as online supple mentary infor -
mation can be submitted to journals, and open 
data sharing has become more commonplace. 
The Task Force anticipates the update will 
provide an even more useful tool for authors and 
medical writers in the coming years. 
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